medicine-technology-1/access-pharmaceuticals-signs-emarketing-agreement-with-imedicor-for-mugard-28tm-29-5249-3/;/a><br

Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2 Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6

[0] Lotus Pharmaceuticals, Inc. Appoints OTC Division Head [0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES [0] Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner [0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain

Breaking Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2 Dynatronics Receives 180-Day NASDAQ Extension 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3 AHIP Statement on Passage of Senate Finance Committee Legislation 59409 1 AHIP Statement on Passage of Senate Finance Committee Legislation 59409 2 Americans United for Lifes Statement on Finance Committee Vote 59407 1 New York Senators Chuck Schumer 28D NY 29 and Kirsten Gillibrand 28D NY 29 Join As Co Sponsors of The Lung Cancer Mortality Reduction Act 59405 1 New York Senators Chuck Schumer 28D NY 29 and Kirsten Gillibrand 28D NY 29 Join As Co Sponsors of The Lung Cancer Mortality Reduction Act 59405 2 New York Senators Chuck Schumer 28D NY 29 and Kirsten Gillibrand 28D NY 29 Join As Co Sponsors of The Lung Cancer Mortality Reduction Act 59405 3

[0] RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793)[0] Dynatronics Receives 180-Day NASDAQ Extension [0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug